| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |